Cargando…
New Technologies for Influenza Vaccines
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vac...
Autores principales: | Rockman, Steven, Laurie, Karen L., Parkes, Simone, Wheatley, Adam, Barr, Ian G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694987/ https://www.ncbi.nlm.nih.gov/pubmed/33172191 http://dx.doi.org/10.3390/microorganisms8111745 |
Ejemplares similares
-
Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?
por: Rockman, Steven, et al.
Publicado: (2020) -
Cell-Based Manufacturing Technology Increases Antigenic Match of Influenza Vaccine and Results in Improved Effectiveness
por: Rockman, Steven, et al.
Publicado: (2022) -
An ELISA-based assay for determining haemagglutinin potency in egg, cell, or recombinant protein derived influenza vaccines
por: Bodle, Jesse, et al.
Publicado: (2023) -
Influenza lineage extinction during the COVID-19 pandemic?
por: Koutsakos, Marios, et al.
Publicado: (2021) -
The importance of influenza vaccination during the COVID‐19 pandemic
por: McCauley, John, et al.
Publicado: (2021)